| First Author | Csóka B | Year | 2018 |
| Journal | FASEB J | Volume | 32 |
| Issue | 2 | Pages | 829-837 |
| PubMed ID | 28982732 | Mgi Jnum | J:270147 |
| Mgi Id | MGI:6277208 | Doi | 10.1096/fj.201700770R |
| Citation | Csoka B, et al. (2018) Adenosine receptors differentially regulate type 2 cytokine production by IL-33-activated bone marrow cells, ILC2s, and macrophages. FASEB J 32(2):829-837 |
| abstractText | Group 2 innate lymphoid cells (ILC2s) represent a rapid source of type 2 cytokines, such as IL-5 and IL-13, and play an important role in orchestrating type 2 immune response. Adenosine is an endogenous purine nucleoside, a catabolite of ATP that binds and activates >/=1 of 4 transmembrane G protein-coupled cell-surface adenosine receptors (ARs)-A1, A2A, A2B, and A3. Here, we studied the role of ARs in the regulation of cytokine production by ILC2s. We found that A2BARs suppress the production of both IL-5 and IL-13 by ILC2s, whereas A2AARs augment IL-5 production and fail to affect IL-13 release. Combined stimulation of all ARs led to the suppression of both IL-5 and IL-13 production, which indicated that A2BARs dominate A2AARs. Both pre- and post-transcriptional processes may be involved in the AR modulation of ILC2 IL-5 and IL-13 production. Thus, we identify adenosine as a novel negative regulator of ILC2 activation.-Csoka, B., Nemeth, Z. H., Duerr, C. U., Fritz, J. H., Pacher, P., Hasko, G. Adenosine receptors differentially regulate type 2 cytokine production by IL-33-activated bone marrow cells, ILC2s, and macrophages. |
